• A development program to support the next pivotal confirmatory phase 3 clinical trial currently being prepared.
• A companion diagnostic test to identify HLA-A*02 positive cancer patients eligible for treatment with Tedopi®.
Nantes, France – November 21, 2023, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces a collaboration agreement with GenDx (Eurobio Scientific Group, a key player in the field of in vitro diagnostics) to develop and validate a companion diagnostic test (CDx) as part of the preparation of the pivotal confirmatory phase 3 clinical trial of Tedopi®, a cancer vaccine candidate, as a second line of treatment in non-small cell lung cancer (NSCLC ). GenDx, one of the pioneering companies in the field of HLA typing, develops and markets innovative molecular diagnostics, particularly in the field of high-resolution HLA typing and related molecular diagnostic tests.